US11974720B2 - Medical device accessory mounting system - Google Patents
Medical device accessory mounting system Download PDFInfo
- Publication number
- US11974720B2 US11974720B2 US17/371,252 US202117371252A US11974720B2 US 11974720 B2 US11974720 B2 US 11974720B2 US 202117371252 A US202117371252 A US 202117371252A US 11974720 B2 US11974720 B2 US 11974720B2
- Authority
- US
- United States
- Prior art keywords
- connecting structure
- ridges
- accessory
- handle
- valleys
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active, expires
Links
- 239000012530 fluid Substances 0.000 description 82
- 238000007726 management method Methods 0.000 description 30
- 239000012636 effector Substances 0.000 description 28
- -1 polytetrafluoroethylene Polymers 0.000 description 17
- 239000000463 material Substances 0.000 description 14
- 238000000034 method Methods 0.000 description 14
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 8
- 229910001182 Mo alloy Inorganic materials 0.000 description 7
- 238000004891 communication Methods 0.000 description 7
- 230000006735 deficit Effects 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 238000010792 warming Methods 0.000 description 6
- 229920000728 polyester Polymers 0.000 description 5
- 239000004814 polyurethane Substances 0.000 description 5
- 229920002635 polyurethane Polymers 0.000 description 5
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- 239000004952 Polyamide Substances 0.000 description 4
- 239000004698 Polyethylene Substances 0.000 description 4
- 239000004743 Polypropylene Substances 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- 229910000856 hastalloy Inorganic materials 0.000 description 4
- 238000002595 magnetic resonance imaging Methods 0.000 description 4
- 229910052697 platinum Inorganic materials 0.000 description 4
- 229920002647 polyamide Polymers 0.000 description 4
- 229920000573 polyethylene Polymers 0.000 description 4
- 229920000139 polyethylene terephthalate Polymers 0.000 description 4
- 239000005020 polyethylene terephthalate Substances 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 229920001155 polypropylene Polymers 0.000 description 4
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 4
- 229910001220 stainless steel Inorganic materials 0.000 description 4
- 239000010935 stainless steel Substances 0.000 description 4
- 230000000007 visual effect Effects 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 229920000106 Liquid crystal polymer Polymers 0.000 description 3
- 239000004977 Liquid-crystal polymers (LCPs) Substances 0.000 description 3
- 229920002614 Polyether block amide Polymers 0.000 description 3
- 239000004721 Polyphenylene oxide Substances 0.000 description 3
- 229910045601 alloy Inorganic materials 0.000 description 3
- 239000000956 alloy Substances 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 239000000919 ceramic Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 3
- 229910052737 gold Inorganic materials 0.000 description 3
- 239000010931 gold Substances 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000005291 magnetic effect Effects 0.000 description 3
- 229910001000 nickel titanium Inorganic materials 0.000 description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 2
- 229910000881 Cu alloy Inorganic materials 0.000 description 2
- 101710112752 Cytotoxin Proteins 0.000 description 2
- 239000004812 Fluorinated ethylene propylene Substances 0.000 description 2
- 229940123011 Growth factor receptor antagonist Drugs 0.000 description 2
- 208000000913 Kidney Calculi Diseases 0.000 description 2
- 229920000339 Marlex Polymers 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 206010029148 Nephrolithiasis Diseases 0.000 description 2
- 239000004696 Poly ether ether ketone Substances 0.000 description 2
- 239000004697 Polyetherimide Substances 0.000 description 2
- 239000004642 Polyimide Substances 0.000 description 2
- 239000004734 Polyphenylene sulfide Substances 0.000 description 2
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 2
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 2
- 229910001080 W alloy Inorganic materials 0.000 description 2
- MTHLBYMFGWSRME-UHFFFAOYSA-N [Cr].[Co].[Mo] Chemical compound [Cr].[Co].[Mo] MTHLBYMFGWSRME-UHFFFAOYSA-N 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000000702 anti-platelet effect Effects 0.000 description 2
- 230000001028 anti-proliverative effect Effects 0.000 description 2
- 239000004019 antithrombin Chemical class 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000001588 bifunctional effect Effects 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000000788 chromium alloy Substances 0.000 description 2
- PRQRQKBNBXPISG-UHFFFAOYSA-N chromium cobalt molybdenum nickel Chemical compound [Cr].[Co].[Ni].[Mo] PRQRQKBNBXPISG-UHFFFAOYSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- YOCUPQPZWBBYIX-UHFFFAOYSA-N copper nickel Chemical compound [Ni].[Cu] YOCUPQPZWBBYIX-UHFFFAOYSA-N 0.000 description 2
- 231100000599 cytotoxic agent Toxicity 0.000 description 2
- 239000002619 cytotoxin Substances 0.000 description 2
- 229910000701 elgiloys (Co-Cr-Ni Alloy) Inorganic materials 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 229920000840 ethylene tetrafluoroethylene copolymer Polymers 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229910001092 metal group alloy Inorganic materials 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- DDTIGTPWGISMKL-UHFFFAOYSA-N molybdenum nickel Chemical compound [Ni].[Mo] DDTIGTPWGISMKL-UHFFFAOYSA-N 0.000 description 2
- HLXZNVUGXRDIFK-UHFFFAOYSA-N nickel titanium Chemical compound [Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni] HLXZNVUGXRDIFK-UHFFFAOYSA-N 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 229920009441 perflouroethylene propylene Polymers 0.000 description 2
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 2
- 229920001707 polybutylene terephthalate Polymers 0.000 description 2
- 229920002530 polyetherether ketone Polymers 0.000 description 2
- 229920001601 polyetherimide Polymers 0.000 description 2
- 229920001721 polyimide Polymers 0.000 description 2
- 229920000098 polyolefin Polymers 0.000 description 2
- 229920006324 polyoxymethylene Polymers 0.000 description 2
- 229920006380 polyphenylene oxide Polymers 0.000 description 2
- 229920000069 polyphenylene sulfide Polymers 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 229910052715 tantalum Inorganic materials 0.000 description 2
- GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 description 2
- 239000004753 textile Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000010936 titanium Substances 0.000 description 2
- 229910052719 titanium Inorganic materials 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 210000005167 vascular cell Anatomy 0.000 description 2
- KWPACVJPAFGBEQ-IKGGRYGDSA-N (2s)-1-[(2r)-2-amino-3-phenylpropanoyl]-n-[(3s)-1-chloro-6-(diaminomethylideneamino)-2-oxohexan-3-yl]pyrrolidine-2-carboxamide Chemical compound C([C@@H](N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)CCl)C1=CC=CC=C1 KWPACVJPAFGBEQ-IKGGRYGDSA-N 0.000 description 1
- PUDHBTGHUJUUFI-SCTWWAJVSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-n-[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2r)-2-amino-3-naphthalen-2-ylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-p Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 PUDHBTGHUJUUFI-SCTWWAJVSA-N 0.000 description 1
- ZKMNUMMKYBVTFN-HNNXBMFYSA-N (S)-ropivacaine Chemical compound CCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C ZKMNUMMKYBVTFN-HNNXBMFYSA-N 0.000 description 1
- KHXKESCWFMPTFT-UHFFFAOYSA-N 1,1,1,2,2,3,3-heptafluoro-3-(1,2,2-trifluoroethenoxy)propane Chemical compound FC(F)=C(F)OC(F)(F)C(F)(F)C(F)(F)F KHXKESCWFMPTFT-UHFFFAOYSA-N 0.000 description 1
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 1
- VNDNKFJKUBLYQB-UHFFFAOYSA-N 2-(4-amino-6-chloro-5-oxohexyl)guanidine Chemical compound ClCC(=O)C(N)CCCN=C(N)N VNDNKFJKUBLYQB-UHFFFAOYSA-N 0.000 description 1
- 102400000068 Angiostatin Human genes 0.000 description 1
- 108010079709 Angiostatins Proteins 0.000 description 1
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229910000531 Co alloy Inorganic materials 0.000 description 1
- OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 description 1
- 229920004943 Delrin® Polymers 0.000 description 1
- 229920006055 Durethan® Polymers 0.000 description 1
- 102400001047 Endostatin Human genes 0.000 description 1
- 108010079505 Endostatins Proteins 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 229920000219 Ethylene vinyl alcohol Polymers 0.000 description 1
- 229910000640 Fe alloy Inorganic materials 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 229920003620 Grilon® Polymers 0.000 description 1
- 102000007625 Hirudins Human genes 0.000 description 1
- 108010007267 Hirudins Proteins 0.000 description 1
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
- 229920000271 Kevlar® Polymers 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- JHWNWJKBPDFINM-UHFFFAOYSA-N Laurolactam Chemical compound O=C1CCCCCCCCCCCN1 JHWNWJKBPDFINM-UHFFFAOYSA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 229910001209 Low-carbon steel Inorganic materials 0.000 description 1
- 229910000792 Monel Inorganic materials 0.000 description 1
- 229910000990 Ni alloy Inorganic materials 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 229920000299 Nylon 12 Polymers 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229920000265 Polyparaphenylene Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- QXZUUHYBWMWJHK-UHFFFAOYSA-N [Co].[Ni] Chemical compound [Co].[Ni] QXZUUHYBWMWJHK-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 239000003529 anticholesteremic agent Substances 0.000 description 1
- 229940127226 anticholesterol agent Drugs 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003080 antimitotic agent Substances 0.000 description 1
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 1
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000003339 best practice Methods 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 229960003150 bupivacaine Drugs 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- OGSYQYXYGXIQFH-UHFFFAOYSA-N chromium molybdenum nickel Chemical compound [Cr].[Ni].[Mo] OGSYQYXYGXIQFH-UHFFFAOYSA-N 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000000806 elastomer Substances 0.000 description 1
- 230000005672 electromagnetic field Effects 0.000 description 1
- 229920006351 engineering plastic Polymers 0.000 description 1
- 229960000610 enoxaparin Drugs 0.000 description 1
- 229930013356 epothilone Natural products 0.000 description 1
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical class C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 description 1
- JBKVHLHDHHXQEQ-UHFFFAOYSA-N epsilon-caprolactam Chemical compound O=C1CCCCCN1 JBKVHLHDHHXQEQ-UHFFFAOYSA-N 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- QHSJIZLJUFMIFP-UHFFFAOYSA-N ethene;1,1,2,2-tetrafluoroethene Chemical group C=C.FC(F)=C(F)F QHSJIZLJUFMIFP-UHFFFAOYSA-N 0.000 description 1
- HQQADJVZYDDRJT-UHFFFAOYSA-N ethene;prop-1-ene Chemical group C=C.CC=C HQQADJVZYDDRJT-UHFFFAOYSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 239000004715 ethylene vinyl alcohol Substances 0.000 description 1
- 239000003302 ferromagnetic material Substances 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000002594 fluoroscopy Methods 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 239000003966 growth inhibitor Substances 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 239000002628 heparin derivative Substances 0.000 description 1
- RZXDTJIXPSCHCI-UHFFFAOYSA-N hexa-1,5-diene-2,5-diol Chemical compound OC(=C)CCC(O)=C RZXDTJIXPSCHCI-UHFFFAOYSA-N 0.000 description 1
- 229920001903 high density polyethylene Polymers 0.000 description 1
- 239000004700 high-density polyethylene Substances 0.000 description 1
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 1
- 229940006607 hirudin Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 229910001026 inconel Inorganic materials 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- UGKDIUIOSMUOAW-UHFFFAOYSA-N iron nickel Chemical compound [Fe].[Ni] UGKDIUIOSMUOAW-UHFFFAOYSA-N 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 108010021336 lanreotide Proteins 0.000 description 1
- 229960002437 lanreotide Drugs 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 229920000092 linear low density polyethylene Polymers 0.000 description 1
- 239000004707 linear low-density polyethylene Substances 0.000 description 1
- 229920001684 low density polyethylene Polymers 0.000 description 1
- 239000004702 low-density polyethylene Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 1
- 229960004963 mesalazine Drugs 0.000 description 1
- 239000002905 metal composite material Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N methyl acetate Chemical class COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- MOWMLACGTDMJRV-UHFFFAOYSA-N nickel tungsten Chemical compound [Ni].[W] MOWMLACGTDMJRV-UHFFFAOYSA-N 0.000 description 1
- 229910000623 nickel–chromium alloy Inorganic materials 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000013307 optical fiber Substances 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- VPRUMANMDWQMNF-UHFFFAOYSA-N phenylethane boronic acid Chemical compound OB(O)CCC1=CC=CC=C1 VPRUMANMDWQMNF-UHFFFAOYSA-N 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 239000011112 polyethylene naphthalate Substances 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 229920000417 polynaphthalene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002215 polytrimethylene terephthalate Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 239000005033 polyvinylidene chloride Substances 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000002089 prostaglandin antagonist Substances 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 229960001549 ropivacaine Drugs 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 1
- 229960001940 sulfasalazine Drugs 0.000 description 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- MHSKRLJMQQNJNC-UHFFFAOYSA-N terephthalamide Chemical compound NC(=O)C1=CC=C(C(N)=O)C=C1 MHSKRLJMQQNJNC-UHFFFAOYSA-N 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 239000012815 thermoplastic material Substances 0.000 description 1
- 239000003803 thymidine kinase inhibitor Substances 0.000 description 1
- 108091006106 transcriptional activators Proteins 0.000 description 1
- 108091006107 transcriptional repressors Proteins 0.000 description 1
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 239000010937 tungsten Substances 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B1/00—Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor
- A61B1/00147—Holding or positioning arrangements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B1/00—Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor
- A61B1/00131—Accessories for endoscopes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B1/00—Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor
- A61B1/00064—Constructional details of the endoscope body
- A61B1/00066—Proximal part of endoscope body, e.g. handles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B1/00—Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor
- A61B1/00112—Connection or coupling means
- A61B1/00121—Connectors, fasteners and adapters, e.g. on the endoscope handle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B1/00—Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor
- A61B1/00112—Connection or coupling means
- A61B1/00121—Connectors, fasteners and adapters, e.g. on the endoscope handle
- A61B1/00128—Connectors, fasteners and adapters, e.g. on the endoscope handle mechanical, e.g. for tubes or pipes
Definitions
- the disclosure is directed to a medical device system. More particularly, the disclosure is directed to an accessory mounting system for medical devices.
- Various accessory devices may be used with an endoscopic device to perform various diagnostic and treatment procedures in the imaged cavity.
- flexible ureteroscopy (fURS), gynecology, and other endoscopic procedures may require multiple medical devices and/or accessories.
- the accessory devices may not always be compatible with the endoscopic device.
- the physical configurations of the devices may be difficult to use in conjunction.
- Mechanical connectivity between devices used together may facilitate smoother procedures.
- fURS flexible ureteroscopy
- gynecology gynecology
- Other endoscopic procedures may require multiple medical devices and/or accessories.
- the accessory devices may not always be compatible with the endoscopic device.
- the physical configurations of the devices may be difficult to use in conjunction.
- Mechanical connectivity between devices used together may facilitate smoother procedures.
- each has certain advantages and disadvantages. There is an ongoing need to provide alternative medical devices and fluid delivery systems.
- a medical accessory mounting system may comprise a medical device having a handle and an elongate shaft extending distally from the handle.
- the handle may include at least one connecting structure formed in an outer surface of the handle, the at least one connecting structure comprising a plurality of ridges.
- the at least one connecting structure may be configured to engage with an accessory connecting structure formed on an outer surface of an accessory device.
- the at least one connecting structure further comprises a plurality of valleys, each valley being disposed between adjacent ridges of the plurality of ridges.
- the plurality of ridges are oriented parallel to each other.
- the accessory connecting structure is releasably engageable with the at least one connecting structure without the use of fasteners.
- the accessory connecting structure is releasably engageable with the at least one connecting structure without the use of latches.
- the accessory connecting structure is releasably engageable with the at least one connecting structure without the use of tools.
- the at least one connecting structure includes a first connecting structure and a second connecting structure.
- the accessory connecting structure is engageable with the first connecting structure and the second connecting structure.
- the accessory connecting structure comprises a plurality of ridges and a plurality of valleys.
- a medical accessory mounting system may comprise a medical device having a handle and an elongate shaft extending distally from the handle.
- the handle may include at least one connecting structure formed in an outer surface of the handle, the at least one connecting structure includes a first connecting structure comprising a first plurality of ridges oriented parallel to each other and a second connecting structure comprising a second plurality of ridges oriented parallel to each other.
- the at least one connecting structure may be configured to engage with an accessory connecting structure comprising a plurality of ridges oriented parallel to each other formed on an outer surface of an accessory device.
- the at least one connecting structure is monolithically formed with the outer surface of the handle.
- the accessory connecting structure is monolithically formed with the outer surface of the accessory device.
- the first plurality of ridges are oriented transverse to a longitudinal axis of the handle.
- the second plurality of ridges are oriented transverse to a longitudinal axis of the handle.
- an endoscopic system may comprise an endoscope having a handle and an elongate shaft extending distally from the handle; and an endoscopic accessory device.
- the handle may include at least one connecting structure formed in an outer surface of the handle, the at least one connecting structure comprising a plurality of ridges.
- the at least one connecting structure may be configured to engage with an accessory connecting structure formed on an outer surface of the endoscopic accessory device.
- the at least one connecting structure includes a first connecting structure and a second connecting structure spaced apart from the first connecting structure.
- the at least one connecting structure includes a third connecting structure spaced apart from the first connecting structure and the second connecting structure.
- the accessory connecting structure is engageable with the at least one connecting structure using a male-to-male engagement.
- the at least one connecting structure includes a plurality of ridges and a plurality of valleys, wherein the plurality of ridges are oriented transverse to a longitudinal axis of the handle.
- adjacent ridges of the plurality of ridges are spaced apart from each other by one of the plurality of valleys, each of the ridges and valleys being oriented parallel to each other.
- FIG. 1 illustrates a medical device manipulatable by medical personnel
- FIG. 2 is a perspective view illustrating selected aspects of the medical device of FIG. 1 ;
- FIG. 3 is a perspective view illustrating aspects of a connecting feature provided with the medical device of FIG. 1 ;
- FIG. 4 is a side view illustrating aspects of the connecting feature shown in FIG. 3 ;
- FIG. 5 is an enlarged view illustrating aspects of the connecting feature shown in FIG. 3 ;
- FIG. 6 is a perspective view illustrating selected aspects of an accessory device compatible with the medical device of FIGS. 1 - 5 ;
- FIG. 7 illustrates selected aspects of an accessory device compatible with the medical device of FIGS. 1 - 5 ;
- FIG. 8 illustrates selected aspects of an accessory device compatible with the medical device of FIGS. 1 - 5 ;
- FIGS. 9 A- 9 B illustrate engagement of the accessory device of FIG. 6 with the medical device of FIGS. 1 - 5 ;
- FIGS. 10 A- 10 B illustrate engagement of the accessory device of FIG. 7 with the medical device of FIGS. 1 - 5 ;
- FIG. 11 illustrates engagement of the accessory device of FIG. 8 with the medical device of FIGS. 1 - 5 .
- numeric values are herein assumed to be modified by the term “about,” whether or not explicitly indicated.
- the term “about”, in the context of numeric values, generally refers to a range of numbers that one of skill in the art would consider equivalent to the recited value (e.g., having the same function or result). In many instances, the term “about” may include numbers that are rounded to the nearest significant figure. Other uses of the term “about” (e.g., in a context other than numeric values) may be assumed to have their ordinary and customary definition(s), as understood from and consistent with the context of the specification, unless otherwise specified.
- proximal distal
- distal proximal
- distal proximal
- distal proximal
- proximal distal
- distal proximal
- distal distal
- proximal distal
- distal distal
- proximal distal
- distal distal
- distal may be arbitrarily assigned in an effort to facilitate understanding of the disclosure, and such instances will be readily apparent to the skilled artisan.
- relative terms such as “upstream”, “downstream”, “inflow”, and “outflow” refer to a direction of fluid flow within a lumen, such as a body lumen, a blood vessel, or within a device.
- Still other relative terms, such as “axial”, “circumferential”, “longitudinal”, “lateral”, “radial”, etc. and/or variants thereof generally refer to direction and/or orientation relative to a central longitudinal axis of the disclosed structure or device.
- extent and/or “maximum extent” may be understood to mean a greatest measurement of a stated or identified dimension, while the term “minimum extent” may be understood to mean a smallest measurement of a stated or identified dimension.
- outer extent may be understood to mean a maximum outer dimension
- radial extent may be understood to mean a maximum radial dimension
- longitudinal extent may be understood to mean a maximum longitudinal dimension
- Each instance of an “extent” may be different (e.g., axial, longitudinal, lateral, radial, circumferential, etc.) and will be apparent to the skilled person from the context of the individual usage.
- an “extent” or “maximum extent” may be considered a greatest possible dimension measured according to the intended usage.
- a “minimum extent” may be considered a smallest possible dimension measured according to the intended usage.
- an “extent” may generally be measured orthogonally within a plane and/or cross-section, but may be, as will be apparent from the particular context, measured differently—such as, but not limited to, angularly, radially, circumferentially (e.g., along an arc), etc.
- references in the specification to “an embodiment”, “some embodiments”, “other embodiments”, etc. indicate that the embodiment(s) described may include a particular feature, structure, or characteristic, but every embodiment may not necessarily include the particular feature, structure, or characteristic. Moreover, such phrases are not necessarily referring to the same embodiment. Further, when a particular feature, structure, or characteristic is described in connection with an embodiment, it would be within the knowledge of one skilled in the art to effect the particular feature, structure, or characteristic in connection with other embodiments, whether or not explicitly described, unless clearly stated to the contrary.
- FIGS. 1 - 2 illustrate aspects of a medical device 20 (e.g., an endoscope, etc.) that may be used in conjunction with a fluid management system (not shown).
- the medical device 20 may be a ureteroscope such as a LithoVue′ scope.
- other medical devices such as another endoscope, may be used in addition to or in place of a ureteroscope.
- the medical device 20 may include a handle 22 and an elongate shaft 30 extending distally from the handle 22 .
- the medical device 20 may be configured to deliver fluid from the fluid management system to a treatment site via the elongate shaft 30 , which may be configured to access the treatment site within the patient.
- an inflow pump may be in fluid communication with the medical device 20 and/or the elongate shaft 30 .
- the elongate shaft 30 may include one or more working lumens for receiving a flow of fluid or other medical devices therethrough.
- the medical device 20 is connected to the fluid management system via one or more supply line(s) 40 .
- the medical device 20 may be in electronic communication with a workstation via a wired connection 50 .
- the workstation may include a touch panel computer, an interface box for receiving the wired connection 50 , a cart, and a power supply, among other features.
- the interface box may be configured with a wired or wireless communication connection with a controller of the fluid management system.
- the touch panel computer may include at least a display screen and an image processor.
- the workstation may be a multi-use component (e.g., used for more than one procedure) while the medical device 20 may be a single use device, although this is not required.
- the workstation may be omitted and the medical device 20 may be electronically coupled directly to the controller of the fluid management system.
- the one or more supply line(s) 40 from the fluid management system to the medical device 20 may be formed of a material the helps dampen the peristaltic motion created by the inflow pump.
- the supply line(s) 40 may be formed from small diameter tubing less than or equal to 1/16 inches (1.5875 millimeters) in diameter.
- tubing size may vary based on the application.
- the supply line(s) 40 and/or the tubing may be disposable and provided sterile and ready to use. Different types of tubing may be used for various functions within the fluid management system. For example, one type of tubing may be used for fluid heating and fluid flow control to the medical device 20 while another type of tubing may be used for irrigation within the body and/or the treatment site.
- the medical device 20 may include one or more sensors proximate a distal end 32 of the elongate shaft 30 .
- the medical device 20 may include a pressure sensor 34 at a distal tip of the elongate shaft 30 to measure intracavity pressure within the treatment site.
- the medical device 20 may also include other sensors such as, for example, a temperature sensor 35 , a Fiber Bragg grating optical fiber 37 to detect stresses, and/or an antenna or electromagnetic sensor 36 (e.g., a position sensor).
- the distal end 32 of the elongate shaft 30 and/or the medical device 20 may also include at least one camera 33 to provide a visual feed to the user on a display screen.
- the at least one camera 33 may include two cameras having different communications requirements or protocols so that different information may be relayed to the user by each camera. When so provided, the user may switch back and forth between cameras at will through a touch screen interface and/or a touch panel computer. While not explicitly shown, the elongate shaft 30 may include one or more working lumens for receiving the fluid and/or other medical devices.
- a mapping and navigation system may include an operating table (or other procedural or examination table or chair, etc.) configured to act or function as an electromagnetic generator to generate a magnetic field of a known geometry.
- a position sensor e.g., the electromagnetic sensor 36 , etc.
- the position sensor may be configured for use in sensing a location of the position sensor in the magnetic field of the mapping and navigation system.
- the position sensor may be electronically coupled to a workstation.
- the location of the position sensor can be mathematically determined relative to the electromagnetic field source (e.g., the operating table and/or the electromagnetic generator).
- the workstation and/or control unit may communicate to determine the position of the position sensor relative to the patient.
- the medical device 20 includes the handle 22 coupled to a proximal end of the elongate shaft 30 .
- the handle 22 may have an optional fluid flow on/off switch 23 , which allows the user to control when fluid is flowing through the medical device 20 and into the treatment site.
- the handle 22 may further include other buttons 24 , 26 that perform other various functions.
- the handle 22 may include buttons to control the temperature of the fluid.
- the medical device 20 may also include a drainage port 28 which may be connected to a drainage system (not shown).
- the fluid management system may include an inflow pump configured to pump and/or transfer fluid from a fluid supply source (e.g., a fluid bag, etc.) to the medical device 20 and/or a treatment site within a patient at a fluid flow rate.
- a fluid supply source e.g., a fluid bag, etc.
- the fluid may pass through a fluid warming system for heating fluid to be delivered to the patient via the one or more supply line(s) 78 prior to entering the medical device 20 .
- the fluid management system may be one that may be used in an endoscopic procedure, such as flexible ureteroscopy (fURS) procedures (e.g., ureteroscopy, percutaneous nephrolithotomy (PCNL), benign prostatic hyperplasia (BPH), transurethral resection of the prostate (TURP), etc.), gynecology, and other endoscopic procedures.
- fURS flexible ureteroscopy
- PCNL percutaneous nephrolithotomy
- BPH benign prostatic hyperplasia
- TURP transurethral resection of the prostate
- gynecology gynecology
- Some illustrative fluid warming systems are described in described in commonly assigned U.S. Patent Application Publication No. 2018/0361055, titled AUTOMATED FLUID MANAGEMENT SYSTEM, the entire disclosure of which is hereby incorporated by reference.
- the flow of fluid, the pressure of the fluid, the temperature of the fluid, and/or other operational parameters may be controlled by or at least partially controlled by a controller.
- the controller may be in electronic communication (e.g., wired or wireless) with the medical device 20 , the inflow pump, and/or the fluid warming system to provide control commands and/or to transfer or receive data therebetween.
- the controller may receive data from the medical device 20 such as, but not limited to, pressure data and temperature data.
- the controller may then use the data received from the medical device 20 to control operational parameters of the inflow pump, the fluid warming system, and/or other features.
- the fluid management system may include a vacuum pump and a collection container in fluid communication with one or more collection drapes.
- the vacuum pump may include a plurality of vacuum pumps.
- the collection container may include a plurality of containers, canisters, and/or other receptacles, which may be fluidly connected to each other and/or the vacuum pump.
- the vacuum pump may be operatively and/or electronically connected to the controller.
- the vacuum pump may be disposed adjacent to and/or near the collection container. Other configurations are also contemplated.
- the fluid management system may also include one or more user interface components such as a touch screen interface.
- the touch screen interface includes a display and may include switches or knobs in addition to touch capabilities.
- the controller may include the touch screen interface and/or the display.
- the touch screen interface allows the user to input/adjust various functions of the fluid management system such as, for example flow rate, pressure, or temperature.
- the user may also configure parameters and alarms (such as, but not limited to, an intracavity pressure limit, a system pressure limit, etc.), information to be displayed, and the procedure mode. It is contemplated that other systems configured to receive user input may be used in place of or in addition to the touch screen interface.
- the fluid management system may also include further user interface components such as an optional foot pedal, a heater user interface, a fluid control interface, or other device to manually control various modular systems.
- the optional foot pedal may be used to manually control flow rate.
- the touch screen interface may be operatively connected to or may be a part of the controller.
- the controller may be a computer, tablet computer, or other processing device.
- the controller may be operatively connected to one or more system components such as, for example, the inflow pump, the fluid warming system, a fluid deficit management system, etc. In some embodiments, these features may be integrated into a single unit.
- the controller may be capable of and configured to perform various functions such as calculation, control, computation, display, etc.
- the controller may also be capable of tracking and storing data pertaining to the operations of the fluid management system and each component thereof.
- the controller includes wired and/or wireless network communication capabilities, such as ethernet or Wi-Fi, through which the controller may be connected to, for example, a local area network.
- the controller may also receive signals from one or more of the sensors of the fluid management system.
- the controller may communicate with databases for best practice suggestions and the maintenance of patient records which may be displayed to the user on the display.
- the fluid management system may include visual software or image recognition and analysis software.
- the controller may be configured to include visual software/image recognition software that can detect visual noise based on variations in brightness (e.g., light monitoring), contrast, or color pixilation. If the image provided to the controller is determined to be not sufficiently clear or sharp, the fluid management system may temporarily increase the fluid flow rate or the fluid pressure to flush out debris from the treatment site to sharpen/clear the image.
- the fluid flow rate or the fluid pressure may be manually or automatically increased for a temporary time (e.g., a predetermined time period) or until the field of view is deemed to be sufficiently clear. This temporary increase ensures that the time at which the fluid flow rate or the fluid pressure is increased is limited to ensure that intracavity pressure does not exceed safe limits.
- the fluid management system may automatically adjust the fluid flow rate and/or the fluid pressure based on a measured intracavity temperature and/or a measured pressure, for example when the measured pressure reaches a preset pressure threshold.
- the measured pressure may be an intracavity pressure measured within the treatment site, and the preset pressure threshold may be an intracavity pressure limit.
- the intracavity temperature and/or the intracavity pressure may be measured in situ using a temperature sensor 35 and/or a pressure sensor 34 mounted on the medical device 20 (e.g., FIG. 1 ) used in conjunction with the fluid management system.
- the fluid management system may include pressure monitoring software so that the inflow pump may be configured by the user to be automatically started, stopped, and/or speed adjusted by the fluid management system to maintain a fluid pressure delivered to the treatment site at a target pressure and/or within a predetermined pressure range.
- the pressure sensor 34 may detect intracavity pressure within the treatment site (for example, a kidney or uterus) and automatically alter the fluid flow rate and/or the fluid pressure within the fluid management system based on the measured intracavity (e.g., intrarenal or intrauterine) pressure. If the intracavity pressure is too high, the fluid management system may decrease the fluid flow rate and/or the fluid pressure and if the intracavity pressure is too low, the fluid management system may increase the fluid flow rate and/or the fluid pressure.
- the controller may be configured to calculate a fluid deficit representative of fluid lost, absorbed by the patient, and/or otherwise unaccounted for during a procedure. In some embodiments, the controller may be configured to notify a user when the total fluid deficit reaches a preset fluid deficit limit. In some embodiments, the controller may be configured to stop the inflow pump and/or the vacuum pump when the total fluid deficit reaches the preset fluid deficit limit. In some embodiments, the controller may be configured to notify a user when a total amount of fluid infused reaches a preset fluid infusion limit. In some embodiments, the controller may be configured to stop the inflow pump and/or the vacuum pump when the total amount of fluid infused reaches the preset fluid infusion limit.
- the medical device 20 (e.g., the endoscope, etc.) may be used in conjunction with one or more accessory devices to form a medical device system and/or an endoscopic system.
- a medical accessory mounting system may include the medical device 20 having the handle 22 and the elongate shaft 30 extending distally from the handle 22 .
- the handle 22 may include at least one connecting structure (e.g., ref. 100 , 110 , 120 , 130 ) formed in an outer surface of the handle 22 , as seen in FIGS. 3 - 5 . In the interest of clarity, some features have been omitted from the handle 22 in FIGS. 3 - 5 .
- the at least one connecting structure may include a plurality of ridges (e.g., ref 102 , 112 , 122 , 132 ) and a plurality of valleys (e.g., ref. 104 , 114 , 124 , 134 ), wherein each valley may be disposed between adjacent ridges of the plurality of ridges.
- the connecting structure may include a plurality of ridges alternating with valleys therebetween.
- the at least one connecting structure may be monolithically and/or integrally formed with the outer surface of the handle 22 .
- the ridges and valleys of the connecting structure may be molded, etched, 3-D printed or otherwise formed during the formation of the handle.
- the ridges and valleys of the connecting structure may be molded during the same molding process in which the handle is formed, or the ridges and valleys of the connecting structure may be printed (e.g., 3-D printed) during the same printing process in which the handle is formed.
- the plurality of ridges may be oriented substantially parallel to each other.
- the plurality of ridges and/or the plurality of valleys may be oriented substantially transverse to a central longitudinal axis of the handle 22 and/or the elongate shaft 30 .
- adjacent ridges of the plurality of ridges may be spaced apart from each other by one of the plurality of valleys, each of the ridges and valleys being oriented substantially parallel to each other and/or substantially transverse to the central longitudinal axis of the handle 22 and/or the elongate shaft 30 .
- the at least one connecting structure formed with the handle may include a first connecting structure 100 , a second connecting structure 110 , a third connecting structure 120 , and/or a fourth connecting structure 130 .
- the medical device 20 and/or the handle 22 may include any one of the above referenced connecting structures and/or any combination thereof up to and including all of the above referenced connecting structures.
- the numerical nomenclature used herein is merely for identification purposes, and numerical nomenclature used in the claims may be considered to represent and/or correspond to a minimum number of the above referenced features that are present therein and not specifically to any particular connecting structure as designated by similar or in-common nomenclature.
- the second connecting structure 110 may be spaced apart from the first connecting structure 100 .
- the first connecting structure 100 and the second connecting structure 110 may be disposed on a common side of the handle 22 .
- the first connecting structure 100 and the second connecting structure 110 may be formed in the outer surface of the handle 22 on one side of a plane extending through the handle 22 and having a central longitudinal axis of the handle 22 and/or the elongate shaft 30 disposed within the plane.
- the first connecting structure 100 and/or the second connecting structure 110 may be monolithically and/or integrally formed with the outer surface of the handle 22 .
- the first connecting structure 100 may include a first plurality of ridges 102 and a first plurality of valleys 104 .
- the first plurality of ridges 102 and/or the first plurality of valleys 104 may be oriented substantially parallel to each other.
- the first plurality of ridges 102 and/or the first plurality of valleys 104 may be oriented substantially transverse to the central longitudinal axis of the handle 22 and/or the elongate shaft 30 .
- adjacent ridges of the first plurality of ridges 102 may be spaced apart from each other by one of the first plurality of valleys 104 , each of the ridges and valleys being oriented substantially parallel to each other and/or substantially transverse to the central longitudinal axis of the handle 22 and/or the elongate shaft 30 .
- the first plurality of ridges 102 may extend outward and/or away from the plane extending through the handle 22 and along the central longitudinal axis of the handle 22 and/or the elongate shaft 30 disposed within the plane.
- the first plurality of ridges 102 may extend outward and/or away from the central longitudinal axis at a substantially perpendicular angle to the central longitudinal axis. In some embodiments, the first plurality of ridges 102 may extend outward and/or away from the plane at a substantially perpendicular angle to the plane.
- the second connecting structure 110 may include a second plurality of ridges 112 and a second plurality of valleys 114 .
- the second plurality of ridges 112 and/or the second plurality of valleys 114 may be oriented substantially parallel to each other.
- the second plurality of ridges 112 and/or the second plurality of valleys 114 may be oriented substantially transverse to the central longitudinal axis of the handle 22 and/or the elongate shaft 30 .
- adjacent ridges of the second plurality of ridges 112 may be spaced apart from each other by one of the second plurality of valleys 114 , each of the ridges and valleys being oriented substantially parallel to each other and/or substantially transverse to the central longitudinal axis of the handle 22 and/or the elongate shaft 30 .
- the second plurality of ridges 122 may extend outward and/or away from the plane extending through the handle 22 and along the central longitudinal axis of the handle 22 and/or the elongate shaft 30 disposed within the plane.
- the second plurality of ridges 112 may extend outward and/or away from the central longitudinal axis at a substantially perpendicular angle to the central longitudinal axis. In some embodiments, the second plurality of ridges 112 may extend outward and/or away from the plane at a substantially perpendicular angle to the plane.
- FIG. 4 is a partially rotated view of the handle 22 of the medical device 20 of FIG. 3 illustrating that the at least one connecting structure may include a third connecting structure 120 spaced apart from the first connecting structure 100 and/or the second connecting structure 110 .
- the third connecting structure 120 may be disposed on an opposite side of the handle 22 from the first connecting structure 100 and the second connecting structure 110 .
- first connecting structure 100 and the second connecting structure 110 may be formed in the outer surface of the handle 22 on one side of a plane extending through the handle 22 and having the central longitudinal axis of the handle 22 and/or the elongate shaft 30 disposed within the plane
- the third connecting structure 120 may be formed in the outer surface of the handle 22 on a second side and/or on an opposite side of the plane extending through the handle 22 and having the central longitudinal axis of the handle 22 and/or the elongate shaft 30 disposed within the plane.
- the third connecting structure 120 may be monolithically and/or integrally formed with the outer surface of the handle 22 .
- the third connecting structure 120 may include a third plurality of ridges 122 and a third plurality of valleys 124 .
- the third plurality of ridges 122 and/or the third plurality of valleys 124 may be oriented substantially parallel to each other.
- the third plurality of ridges 122 and/or the third plurality of valleys 124 may be oriented substantially transverse to the central longitudinal axis of the handle 22 and/or the elongate shaft 30 .
- adjacent ridges of the third plurality of ridges 122 may be spaced apart from each other by one of the third plurality of valleys 124 , each of the ridges and valleys being oriented substantially parallel to each other and/or substantially transverse to the central longitudinal axis of the handle 22 and/or the elongate shaft 30 .
- the third plurality of ridges 122 may extend outward and/or away from the plane extending through the handle 22 and along the central longitudinal axis of the handle 22 and/or the elongate shaft 30 disposed within the plane.
- the third plurality of ridges 122 may extend outward and/or away from the central longitudinal axis at a substantially perpendicular angle to the central longitudinal axis. In some embodiments, the third plurality of ridges 122 may extend outward and/or away from the plane at a substantially perpendicular angle to the plane.
- FIG. 5 illustrates a portion of the handle 22 of the medical device 20 , and further illustrates that the at least one connecting structure may include a fourth connecting structure 130 spaced apart from the first connecting structure 100 , the second connecting structure 110 , and/or the third connecting structure 120 , as seen in FIG. 5 .
- the fourth connecting structure 130 may be disposed on a different side of the handle 22 from the first connecting structure 100 , the second connecting structure 110 , and/or the third connecting structure 120 .
- the fourth connecting structure 130 may be formed in the outer surface of the handle 22 with the plane, referred to above as extending through the handle 22 and having the central longitudinal axis of the handle 22 and/or the elongate shaft 30 disposed within the plane, extending through and/or transecting the fourth connecting structure 130 .
- the side of the handle 22 having the fourth connecting structure 130 disposed therein may be oriented at a generally perpendicular angle to the sides having the first, second, and/or third connecting structures.
- the fourth connecting structure 130 may be considered to face towards a top side or a bottom side of the handle 22 .
- the fourth connecting structure 130 may be monolithically and/or integrally formed with the outer surface of the handle 22 .
- the fourth connecting structure 130 may include a fourth plurality of ridges 132 and a fourth plurality of valleys 134 .
- the fourth plurality of ridges 132 and/or the fourth plurality of valleys 134 may be oriented substantially parallel to each other.
- the fourth plurality of ridges 132 and/or the fourth plurality of valleys 134 may be oriented substantially transverse to the central longitudinal axis of the handle 22 and/or the elongate shaft 30 .
- adjacent ridges of the fourth plurality of ridges 132 may be spaced apart from each other by one of the fourth plurality of valleys 134 , each of the ridges and valleys being oriented substantially parallel to each other and/or substantially transverse to the central longitudinal axis of the handle 22 and/or the elongate shaft 30 .
- the fourth plurality of ridges 132 may extend outward and/or away from the central longitudinal axis at a substantially perpendicular angle to the central longitudinal axis.
- the ridges of the connecting structures may be defined by first and second side surfaces intersecting an outward facing surface.
- the first and second side surfaces may extend parallel to one another, and be positioned at a perpendicular angle to the outward facing surface.
- the first and second side surface may interest the outward facing surface at a non-perpendicular angle, such as an acute angle of about 70° to about 88°, about 75° to about 88°, about 80° to about 88°, about 70° to about 85°, about 75° to about 85°, or about 80° to about 85°, for example, or intersect at an obtuse angle of about 92° to about 110°, about 92° to about 105°, about 92° to about 100°, about 95° to about 110°, about 95° to about 105°, or about 95° to about 100°, for example.
- first and second side surfaces may converge toward one another as they extend toward the outward facing surface, or the first and second side surfaces may diverge away from one another as they extend toward the outward facing surface.
- the valleys may define a base surface extending between a side surface of one ridge to a facing side surface of an adjacent ridge.
- an accessory device may include a motorized endoscopic deployment device for controlling an elongated end effector device to capture a target element (e.g., kidney stones or the like).
- the motorized deployment device may be compatible with the medical device 20 (e.g., the endoscope) or may be integrated with the medical device 20 in a monolithic handle.
- the elongated end effector device may refer to any one of a number of devices compatible with and actuated by the motorized deployment device.
- the elongated end effector device may be a retrieval device for capturing kidney stones, a laser fiber device, a therapy needle, snares, forceps, band ligation devices, etc.
- any of the elongated end effector devices may be fitted with, for example, a handle sized and shaped to be used with the motorized deployment device.
- any elongated end effector device compatible with and fitted with an appropriate handle may also be used with the motorized deployment device.
- Other accessory devices are also contemplated.
- the at least one connecting structure may be configured to engage with an accessory connecting structure (e.g., FIGS. 6 - 8 , ref. 210 , 310 , 410 ) formed on an outer surface of an accessory device (e.g., FIGS. 6 - 8 , ref. 200 , 300 , 400 ).
- the accessory device described herein may include and/or may be an accessory device handle.
- the accessory connecting structure may comprise a plurality of ridges (e.g., FIGS. 6 - 8 , ref. 212 , 312 , 412 ) and a plurality of valleys (e.g., FIGS. 6 - 8 , ref. 214 , 314 , 414 ), wherein each valley may be disposed between adjacent ridges of the plurality of ridges.
- the plurality of ridges of the accessory connecting structure may be oriented substantially parallel to each other.
- the ridges of the accessory connecting structures of may be defined by first and second side surfaces intersecting an outward facing surface.
- first and second side surfaces may extend parallel to one another, and be positioned at a perpendicular angle to the outward facing surface.
- the first and second side surface may interest the outward facing surface at a non-perpendicular angle, such as an acute angle of about 70° to about 88°, about 75° to about 88°, about 80° to about 88°, about 70° to about 85°, about 75° to about 85°, or about 80° to about 85°, for example, or intersect at an obtuse angle of about 92° to about 110°, about 92° to about 105°, about 92° to about 100°, about 95° to about 110°, about 95° to about 105°, or about 95° to about 100°, for example.
- a non-perpendicular angle such as an acute angle of about 70° to about 88°, about 75° to about 88°, about 80° to about 88°, about 70° to about 85°, about 75° to about 85°, or about 80° to about 85°, for example, or intersect at an obtuse angle of about 92° to about 110°, about 92° to about 105°
- first and second side surfaces may converge toward one another as they extend toward the outward facing surface, or the first and second side surfaces may diverge away from one another as they extend toward the outward facing surface.
- the valleys may define a base surface extending between a side surface of one ridge to a facing side surface of an adjacent ridge.
- FIG. 6 illustrates a portion of an example accessory device 200 .
- the accessory device 200 may include an accessory device handle 202 and/or an end effector device 204 .
- an outer surface of the accessory device 200 and/or the accessory device handle 202 may include an accessory connecting structure 210 comprising a plurality of ridges 212 and a plurality of valleys 214 , wherein each valley may be disposed between adjacent ridges of the plurality of ridges 212 .
- the plurality of ridges 212 and/or the plurality of valleys 214 may be oriented substantially parallel to each other. In some embodiments, the plurality of ridges 212 and/or the plurality of valleys 214 may be oriented substantially transverse to a central longitudinal axis of the accessory device 200 , the accessory device handle 202 , and/or the end effector device 204 .
- adjacent ridges of the plurality of ridges 212 may be spaced apart from each other by one of the plurality of valleys 214 , each of the ridges and valleys being oriented substantially parallel to each other and/or extending radially outward from the central longitudinal axis of the accessory device 200 , the accessory device handle 202 , and/or the end effector device 204 .
- the plurality of ridges 212 may extend radially outward and/or away from the central longitudinal axis of the accessory device 200 , the accessory device handle 202 , and/or the end effector device 204 at a substantially right angle to the central longitudinal axis of the accessory device 200 , the accessory device handle 202 , and/or the end effector device 204 .
- the plurality of ridges 212 may be monolithically and/or integrally formed with the outer surface of the accessory device 200 and/or the accessory device handle 202 .
- FIG. 7 illustrates a portion of an example accessory device 300 .
- the accessory device 300 may include a flattened body 302 including a multi-purpose clip 320 attached thereto.
- the multi-purpose clip 320 may be hingedly and/or pivotably connected to the flattened body 302 .
- the multi-purpose clip 320 may be useful and/or beneficial for tool management (e.g., containing and/or holding a guidewire, an end effector device, etc.).
- the accessory device 300 may have one or more features other than or in addition to the multi-purpose clip 320 . Other configurations are also contemplated.
- an outer surface of the accessory device 300 and/or the flattened body 302 may include an accessory connecting structure 310 comprising a plurality of ridges 312 and a plurality of valleys 314 , wherein each valley may be disposed between adjacent ridges of the plurality of ridges 312 .
- the plurality of ridges 312 and/or the plurality of valleys 314 may be oriented substantially parallel to each other. In some embodiments, adjacent ridges of the plurality of ridges 312 may be spaced apart from each other by one of the plurality of valleys 314 , each of the ridges and valleys being oriented substantially parallel to each other and/or extending outward and/or away from the flattened body 302 of the accessory device 300 . In some embodiments, the plurality of ridges 312 may extend in an opposite direction from and/or away from the multi-purpose clip 320 with respect to the flattened body 302 .
- the plurality of ridges 312 may extend radially outward and/or away from the flattened body 302 of the accessory device 300 at a substantially perpendicular angle to the flattened body 302 of the accessory device 300 . In some embodiments, the plurality of ridges 312 may be monolithically and/or integrally formed with the outer surface of the accessory device 300 and/or the flattened body 302 of the accessory device 300 .
- FIG. 8 illustrates an example accessory device 400 .
- the accessory device 400 may include and/or may be an accessory device handle configured to receive an end effector device.
- an outer surface of the accessory device 400 and/or the accessory device handle may include an accessory connecting structure 410 comprising a plurality of ridges 412 and a plurality of valleys 414 , wherein each valley may be disposed between adjacent ridges of the plurality of ridges 412 .
- a body 420 of the accessory device 400 and/or the accessory device handle may include a longitudinally oriented slot 416 extending from a proximal end 402 of the accessory device 400 and/or the accessory device handle to a distal end 404 of the accessory device 400 and/or the accessory device handle.
- the longitudinally oriented slot 416 may be configured to receive an end effector device therein in a transverse direction relative to a central longitudinal axis of the accessory device 400 and/or the accessory device handle, thereby negating the need to feed the end effector device axially through the accessory device 400 and/or the accessory device handle.
- the accessory device 400 may be either of a SeguraTM or a DakotaTM handle.
- the plurality of ridges 412 and/or the plurality of valleys 414 may be oriented substantially parallel to each other. In some embodiments, the plurality of ridges 412 and/or the plurality of valleys 414 may be oriented substantially transverse to a central longitudinal axis of the accessory device 400 and/or the accessory device handle. In some embodiments, adjacent ridges of the plurality of ridges 412 may be spaced apart from each other by one of the plurality of valleys 414 , each of the ridges and valleys being oriented substantially parallel to each other and/or extending radially outward from the central longitudinal axis of the accessory device 400 and/or the accessory device handle.
- the plurality of ridges 412 may extend radially outward and/or away from the central longitudinal axis of the accessory device 400 and/or the accessory device handle at a substantially perpendicular angle to the central longitudinal axis of the accessory device 400 and/or the accessory device handle. In some embodiments, the plurality of ridges 412 may be monolithically and/or integrally formed with the outer surface of the accessory device 400 and/or the accessory device handle.
- a slide may slide over the body 420 of the accessory device 400 and/or the accessory device handle.
- a male luer may be attached to a distal end of the slide, while a shaft (e.g., a pull wire) of the end effector device is held by a jaw vise including a plurality of jaws at the proximal end 402 of the accessory device 400 and/or the body 420 .
- a cap 430 (e.g., FIG. 11 ) may force the plurality of jaws closed around the shaft of the end effector device as the cap 430 is screwed onto the body 420 .
- the body 420 may have a through-lumen for the shaft of the elongated end effector device.
- the slide may move relative to the body 420 and the shaft of the end effector device.
- An outer sheath of the end effector device may be connected via a female luer to the male luer and extend to cover the end effector at the distal end of the end effector device.
- a stroke-limiter in the accessory device 400 and/or the accessory device handle may govern the travel of the slide relative to the end effector size.
- end effector devices compatible with the accessory device 400 and/or the accessory device handle may include a stone/particle retrieval basket for capturing objects at a distal end of the endoscopic shaft, a laser fiber device for fragmenting and/or cauterizing objects at the distal end of the endoscopic shaft, a therapy needle for puncturing and/or supplying medicament to a treatment site, a snare for capturing objects at the distal end of the endoscopic shaft, a forceps for capturing and/or grasping objects at the distal end of the endoscopic shaft, and a band ligation device.
- Other end effector devices are also contemplated.
- FIGS. 9 A and 9 B illustrate engagement of the accessory device 200 with a portion of the handle 22 of the medical device 20 .
- the at least one connecting structure of the medical device 20 may be configured to engage with the accessory connecting structure 210 formed on the outer surface of the accessory device 200 .
- FIGS. 9 A and 9 B illustrate engagement of the accessory device 200 with the fourth connecting structure 130 formed on the outer surface of the medical device 20 and/or the handle 22 .
- the accessory device 200 and/or the accessory connecting structure 210 may be engageable with the first connecting structure 100 , the second connecting structure 110 (not shown), the third connecting structure 120 (not shown), and/or the fourth connecting structure 130 .
- the accessory device 200 and/or the accessory connecting structure 210 is shown engaging the fourth connecting structure 130 of the handle 22 of the medical device 20 and is described accordingly.
- the at least one connecting structure of the medical device 20 may be configured to engage with the accessory connecting structure 210 via an interference fit, a press fit, a friction fit, and the like, as seen in FIG. 9 B .
- Other means of engagement are also contemplated.
- the plurality of ridges 212 of the accessory connecting structure 210 may be configured to engage with and/or be received by the plurality of valleys (e.g., the fourth plurality of valleys 134 ) of the at least one connecting structure (e.g., the fourth connecting structure 130 ), and the plurality of ridges (e.g., the fourth plurality of ridges 132 ) of the at least one connecting structure (e.g., the fourth connecting structure 130 ) may be configured to engage with and/or be received by the plurality of valleys 214 of the accessory connecting structure 210 .
- the accessory connecting structure 210 may be engageable with the at least one connecting structure (e.g., the fourth connecting structure 130 ) using a male-to-male engagement.
- the side surfaces of the ridges 212 of the accessory connecting structure 210 may frictionally engage and press against the juxtaposed side surfaces of the ridges 132 of the connecting structure 130 of the handle 22 .
- the accessory device 200 may be configured to be oriented with a central longitudinal axis substantially parallel to the central longitudinal axis of the medical device 20 , the handle 22 , and/or the elongate shaft 30 when the accessory connecting structure 210 is engaged with the at least one connecting structure (e.g., the first connecting structure 100 , the second connecting structure 110 , the third connecting structure 120 , and/or the fourth connecting structure 130 ).
- the at least one connecting structure e.g., the first connecting structure 100 , the second connecting structure 110 , the third connecting structure 120 , and/or the fourth connecting structure 130 .
- the accessory connecting structure 210 may be releasably engageable with the at least one connecting structure (e.g., the first connecting structure 100 , the second connecting structure 110 , the third connecting structure 120 , and/or the fourth connecting structure 130 ) without the use of fasteners (e.g., screws, pins, clips, etc.).
- the accessory connecting structure 210 may be releasably engageable with the at least one connecting structure (e.g., the first connecting structure 100 , the second connecting structure 110 , the third connecting structure 120 , and/or the fourth connecting structure 130 ) without the use of latches.
- the accessory connecting structure 210 may be releasably engageable with the at least one connecting structure (e.g., the first connecting structure 100 , the second connecting structure 110 , the third connecting structure 120 , and/or the fourth connecting structure 130 ) without the use of tools.
- the at least one connecting structure e.g., the first connecting structure 100 , the second connecting structure 110 , the third connecting structure 120 , and/or the fourth connecting structure 130
- FIGS. 10 A and 10 B illustrate engagement of the accessory device 300 with a portion of the handle 22 of the medical device 20 . Since it is not necessary to understand the engagement, the multi-purpose clip 320 has been omitted from FIGS. 10 A and 10 B .
- the at least one connecting structure of the medical device 20 may be configured to engage with the accessory connecting structure 310 formed on the outer surface of the accessory device 300 .
- FIGS. 10 A and 10 B illustrate engagement of the accessory device 300 with the first connecting structure 100 formed on the outer surface of the medical device 20 and/or the handle 22 .
- the accessory device 300 and/or the accessory connecting structure 310 may be engageable with the first connecting structure 100 , the second connecting structure 110 (not shown), the third connecting structure 120 (not shown), and/or the fourth connecting structure 130 .
- the accessory device 300 and/or the accessory connecting structure 310 is shown engaging the first connecting structure 100 of the handle 22 of the medical device 20 and is described accordingly.
- the at least one connecting structure of the medical device 20 may be configured to engage with the accessory connecting structure 310 via an interference fit, a press fit, a friction fit, and the like, as seen in FIG. 10 B .
- Other means of engagement are also contemplated.
- the plurality of ridges 312 of the accessory connecting structure 310 may be configured to engage with and/or be received by the plurality of valleys (e.g., the first plurality of valleys 104 ) of the at least one connecting structure (e.g., the first connecting structure 100 ), and the plurality of ridges (e.g., the first plurality of ridges 102 ) of the at least one connecting structure (e.g., the first connecting structure 100 ) may be configured to engage with and/or be received by the plurality of valleys 314 of the accessory connecting structure 310 .
- the accessory connecting structure 310 may be engageable with the at least one connecting structure (e.g., the first connecting structure 100 ) using a male-to-male engagement.
- the side surfaces of the ridges 312 of the accessory connecting structure 310 may frictionally engage and press against the juxtaposed side surfaces of the ridges 102 of the connecting structure 100 of the handle 22 .
- the accessory device 300 may be configured to be oriented with flattened body 302 substantially transverse to and without intersecting the central longitudinal axis of the medical device 20 , the handle 22 , and/or the elongate shaft 30 when the accessory connecting structure 310 is engaged with the at least one connecting structure (e.g., the first connecting structure 100 , the second connecting structure 110 , the third connecting structure 120 , and/or the fourth connecting structure 130 ).
- the at least one connecting structure e.g., the first connecting structure 100 , the second connecting structure 110 , the third connecting structure 120 , and/or the fourth connecting structure 130 .
- the accessory connecting structure 310 may be releasably engageable with the at least one connecting structure (e.g., the first connecting structure 100 , the second connecting structure 110 , the third connecting structure 120 , and/or the fourth connecting structure 130 ) without the use of fasteners (e.g., screws, pins, clips, etc.). In some embodiments, the accessory connecting structure 310 may be releasably engageable with the at least one connecting structure (e.g., the first connecting structure 100 , the second connecting structure 110 , the third connecting structure 120 , and/or the fourth connecting structure 130 ) without the use of latches.
- the at least one connecting structure e.g., the first connecting structure 100 , the second connecting structure 110 , the third connecting structure 120 , and/or the fourth connecting structure 130
- the accessory connecting structure 310 may be releasably engageable with the at least one connecting structure (e.g., the first connecting structure 100 , the second connecting structure 110 , the third connecting structure 120 , and/or the fourth connecting structure 130 ) without the use of tools.
- the at least one connecting structure e.g., the first connecting structure 100 , the second connecting structure 110 , the third connecting structure 120 , and/or the fourth connecting structure 130
- FIG. 11 illustrates engagement of the accessory device 400 with a portion of the handle 22 of the medical device 20 .
- the at least one connecting structure of the medical device 20 may be configured to engage with the accessory connecting structure 410 formed on the outer surface of the accessory device 400 .
- FIG. 11 illustrates engagement of the accessory device 400 with the fourth connecting structure 130 formed on the outer surface of the medical device 20 and/or the handle 22 .
- the accessory device 400 and/or the accessory connecting structure 410 may be engageable with the first connecting structure 100 , the second connecting structure 110 (not shown), the third connecting structure 120 (not shown), and/or the fourth connecting structure 130 .
- the accessory device 400 and/or the accessory connecting structure 410 is shown engaging the fourth connecting structure 130 of the handle 22 of the medical device 20 and is described accordingly.
- the at least one connecting structure of the medical device 20 may be configured to engage with the accessory connecting structure 410 via an interference fit, a press fit, a friction fit, and the like, as seen in FIG. 11 .
- Other means of engagement are also contemplated.
- the plurality of ridges 412 of the accessory connecting structure 410 may be configured to engage with and/or be received by the plurality of valleys (e.g., the fourth plurality of valleys 134 ) of the at least one connecting structure (e.g., the fourth connecting structure 130 ), and the plurality of ridges (e.g., the fourth plurality of ridges 132 ) of the at least one connecting structure (e.g., the fourth connecting structure 130 ) may be configured to engage with and/or be received by the plurality of valleys 414 of the accessory connecting structure 410 .
- the accessory connecting structure 410 may be engageable with the at least one connecting structure (e.g., the fourth connecting structure 130 ) using a male-to-male engagement.
- the side surfaces of the ridges 412 of the accessory connecting structure 410 may frictionally engage and press against the juxtaposed side surfaces of the ridges 132 of the connecting structure 130 of the handle 22 .
- the accessory device 400 may be configured to be oriented with a central longitudinal axis substantially parallel to the central longitudinal axis of the medical device 20 , the handle 22 , and/or the elongate shaft 30 when the accessory connecting structure 410 is engaged with the at least one connecting structure (e.g., the first connecting structure 100 , the second connecting structure 110 , the third connecting structure 120 , and/or the fourth connecting structure 130 ).
- the at least one connecting structure e.g., the first connecting structure 100 , the second connecting structure 110 , the third connecting structure 120 , and/or the fourth connecting structure 130 .
- the accessory connecting structure 410 may be releasably engageable with the at least one connecting structure (e.g., the first connecting structure 100 , the second connecting structure 110 , the third connecting structure 120 , and/or the fourth connecting structure 130 ) without the use of fasteners (e.g., screws, pins, clips, etc.). In some embodiments, the accessory connecting structure 410 may be releasably engageable with the at least one connecting structure (e.g., the first connecting structure 100 , the second connecting structure 110 , the third connecting structure 120 , and/or the fourth connecting structure 130 ) without the use of latches.
- the at least one connecting structure e.g., the first connecting structure 100 , the second connecting structure 110 , the third connecting structure 120 , and/or the fourth connecting structure 130
- the accessory connecting structure 410 may be releasably engageable with the at least one connecting structure (e.g., the first connecting structure 100 , the second connecting structure 110 , the third connecting structure 120 , and/or the fourth connecting structure 130 ) without the use of tools.
- the at least one connecting structure e.g., the first connecting structure 100 , the second connecting structure 110 , the third connecting structure 120 , and/or the fourth connecting structure 130 .
- the materials that can be used for the various components of the system(s) and the various elements thereof disclosed herein may include those commonly associated with medical devices.
- the following discussion refers to the system. However, this is not intended to limit the devices and methods described herein, as the discussion may be applied to other elements, members, components, or devices disclosed herein, such as, but not limited to, the fluid management system, the medical device, the handle, the elongate shaft, the accessory device, the inflow pump, the fluid warming system, the controller, the supply line(s), the workstation, the display screen(s), etc. and/or elements or components thereof.
- the system, and/or components thereof may be made from a metal, metal alloy, polymer (some examples of which are disclosed below), a metal-polymer composite, ceramics, combinations thereof, and the like, or other suitable material.
- suitable polymers may include polytetrafluoroethylene (PTFE), ethylene tetrafluoroethylene (ETFE), fluorinated ethylene propylene (FEP), polyoxymethylene (POM, for example, DELRIN® available from DuPont), polyether block ester, polyurethane (for example, Polyurethane 85A), polypropylene (PP), polyvinylchloride (PVC), polyether-ester (for example, ARNITEL® available from DSM Engineering Plastics), ether or ester based copolymers (for example, butylene/poly(alkylene ether) phthalate and/or other polyester elastomers such as HYTREL® available from DuPont), polyamide (for example, DURETHAN® available from Bayer or CRISTAMID® available from Elf Atochem), elastomeric polyamides, block polyamide/ethers, polyether block amide (PEBA, for example available under the trade name PEBAX®), ethylene vinyl acetate
- suitable metals and metal alloys include stainless steel, such as 304V, 304L, and 316LV stainless steel; mild steel; nickel-titanium alloy such as linear-elastic and/or super-elastic nitinol; other nickel alloys such as nickel-chromium-molybdenum alloys (e.g., UNS: N06625 such as INCONEL® 625, UNS: N06022 such as HASTELLOY® C-22®, UNS: N10276 such as HASTELLOY® C276®, other HASTELLOY® alloys, and the like), nickel-copper alloys (e.g., UNS: N04400 such as MONEL® 400, NICKELVAC® 400, NICORROS® 400, and the like), nickel-cobalt-chromium-molybdenum alloys (e.g., UNS: R30035 such as MP35-N® and the like), nickel-molybdenum alloys (e.g.,
- portions or all of the system, and/or components thereof may also be doped with, made of, or otherwise include a radiopaque material.
- Radiopaque materials are understood to be materials capable of producing a relatively bright image on a fluoroscopy screen or another imaging technique during a medical procedure. This relatively bright image aids the user of the system in determining its location.
- Some examples of radiopaque materials can include, but are not limited to, gold, platinum, palladium, tantalum, tungsten alloy, polymer material loaded with a radiopaque filler, and the like. Additionally, other radiopaque marker bands and/or coils may also be incorporated into the design of the system to achieve the same result.
- MM Magnetic Resonance Imaging
- the system, and/or components or portions thereof may be made of a material that does not substantially distort the image and create substantial artifacts (i.e., gaps in the image).
- Certain ferromagnetic materials may not be suitable because they may create artifacts in an MRI image.
- the system, or portions thereof may also be made from a material that the MRI machine can image.
- Some materials that exhibit these characteristics include, for example, tungsten, cobalt-chromium-molybdenum alloys (e.g., UNS: R30003 such as ELGILOY®, PHYNOX®, and the like), nickel-cobalt-chromium-molybdenum alloys (e.g., UNS: R30035 such as MP35-N® and the like), nitinol, and the like, and others.
- cobalt-chromium-molybdenum alloys e.g., UNS: R30003 such as ELGILOY®, PHYNOX®, and the like
- nickel-cobalt-chromium-molybdenum alloys e.g., UNS: R30035 such as MP35-N® and the like
- nitinol and the like, and others.
- the system and/or other elements disclosed herein may include and/or be formed from a textile material.
- suitable textile materials may include synthetic yarns that may be flat, shaped, twisted, textured, pre-shrunk or un-shrunk.
- Synthetic biocompatible yarns suitable for use in the present invention include, but are not limited to, polyesters, including polyethylene terephthalate (PET) polyesters, polypropylenes, polyethylenes, polyurethanes, polyolefins, polyvinyls, poly methyl acetates, polyamides, naphthalene dicarboxylene derivatives, natural silk, and polytetrafluoroethylenes.
- PET polyethylene terephthalate
- the synthetic yarns may be a metallic yarn or a glass or ceramic yarn or fiber.
- Useful metallic yarns include those yarns made from or containing stainless steel, platinum, gold, titanium, tantalum or a Ni—Co—Cr-based alloy.
- the yarns may further include carbon, glass or ceramic fibers.
- the yarns are made from thermoplastic materials including, but not limited to, polyesters, polypropylenes, polyethylenes, polyurethanes, polynaphthalenes, polytetrafluoroethylenes, and the like.
- the yarns may be of the multifilament, monofilament, or spun types. The type and denier of the yarn chosen may be selected in a manner which forms a biocompatible and implantable prosthesis and, more particularly, a vascular structure having desirable properties.
- the system and/or other elements disclosed herein may include and/or be treated with a suitable therapeutic agent.
- suitable therapeutic agents may include anti-thrombogenic agents (such as heparin, heparin derivatives, urokinase, and PPack (dextro-phenylalanine proline arginine chloromethyl ketone)); anti-proliferative agents (such as enoxaparin, angiopeptin, monoclonal antibodies capable of blocking smooth muscle cell proliferation, hirudin, and acetylsalicylic acid); anti-inflammatory agents (such as dexamethasone, prednisolone, corticosterone, budesonide, estrogen, sulfasalazine, and mesalamine); antineoplastic/antiproliferative/anti-mitotic agents (such as paclitaxel, 5-fluorouracil, cisplatin, vinblastine, vincristine, epothilones, end
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Surgery (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Mechanical Engineering (AREA)
- Surgical Instruments (AREA)
Abstract
Description
Claims (18)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/371,252 US11974720B2 (en) | 2020-07-15 | 2021-07-09 | Medical device accessory mounting system |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063051996P | 2020-07-15 | 2020-07-15 | |
US17/371,252 US11974720B2 (en) | 2020-07-15 | 2021-07-09 | Medical device accessory mounting system |
Publications (2)
Publication Number | Publication Date |
---|---|
US20220015611A1 US20220015611A1 (en) | 2022-01-20 |
US11974720B2 true US11974720B2 (en) | 2024-05-07 |
Family
ID=79291601
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/371,252 Active 2041-12-14 US11974720B2 (en) | 2020-07-15 | 2021-07-09 | Medical device accessory mounting system |
Country Status (1)
Country | Link |
---|---|
US (1) | US11974720B2 (en) |
Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5431150A (en) * | 1993-01-27 | 1995-07-11 | Olympus Optical Co., Ltd. | Covered endoscope having a cap cover for shielding a dilation tube cap with which a dilation tube is coupled |
US5514074A (en) * | 1993-02-12 | 1996-05-07 | Olympus Optical Co., Ltd. | Endoscope apparatus of an endoscope cover system for preventing buckling of an endoscope cover |
US5695491A (en) | 1994-11-22 | 1997-12-09 | Washington Research Foundation | Endoscopic accessory and containment system |
US6893393B2 (en) | 2003-02-19 | 2005-05-17 | Boston Scientific Scimed., Inc. | Guidewire locking device and method |
US7223230B2 (en) | 2002-09-06 | 2007-05-29 | C. R. Bard, Inc. | External endoscopic accessory control system |
US7615004B2 (en) | 2006-03-30 | 2009-11-10 | Ethicon Endo-Surgery, Inc. | Endoscopic ancillary attachment devices |
US8007432B2 (en) | 2007-01-26 | 2011-08-30 | Ethicon Endo-Surgery, Inc. | Endoscopic accessory control mechanism |
US8734327B2 (en) | 2008-04-29 | 2014-05-27 | Cook Medical Technologies Llc | Device platform for medical procedures |
US20150164307A1 (en) | 2013-12-12 | 2015-06-18 | Gyrus Acmi, Inc. (D.B.A. Olympus Surgical Technologies America) | Endoscope Tool Position Holder |
US9254077B2 (en) | 2007-04-02 | 2016-02-09 | Cook Medical Technologies Llc | Endoscopic apparatus having an outer rail |
US20160089008A1 (en) | 2014-09-29 | 2016-03-31 | Cook Medical Technologies Llc | Endoscope mountable visualization device quick-connect/release handle attachment mechanism |
US9486125B2 (en) | 2009-07-08 | 2016-11-08 | Endoguard Limited | Accessory clip for an endoscope |
US20170188796A1 (en) * | 2016-01-04 | 2017-07-06 | Endovate Llc | Overtube Device and Method of Use |
US9723973B2 (en) | 2013-08-20 | 2017-08-08 | Cook Medical Technologies Llc | Endoscope mountable visualization device and handle |
US20180361055A1 (en) | 2017-06-19 | 2018-12-20 | Boston Scientific Scimed, Inc. | Automated fluid management system |
-
2021
- 2021-07-09 US US17/371,252 patent/US11974720B2/en active Active
Patent Citations (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5431150A (en) * | 1993-01-27 | 1995-07-11 | Olympus Optical Co., Ltd. | Covered endoscope having a cap cover for shielding a dilation tube cap with which a dilation tube is coupled |
US5514074A (en) * | 1993-02-12 | 1996-05-07 | Olympus Optical Co., Ltd. | Endoscope apparatus of an endoscope cover system for preventing buckling of an endoscope cover |
US5695491A (en) | 1994-11-22 | 1997-12-09 | Washington Research Foundation | Endoscopic accessory and containment system |
US7223230B2 (en) | 2002-09-06 | 2007-05-29 | C. R. Bard, Inc. | External endoscopic accessory control system |
US6893393B2 (en) | 2003-02-19 | 2005-05-17 | Boston Scientific Scimed., Inc. | Guidewire locking device and method |
US7803107B2 (en) | 2003-02-19 | 2010-09-28 | Boston Scientific Scimed, Inc. | Guidewire locking device and method |
US7615004B2 (en) | 2006-03-30 | 2009-11-10 | Ethicon Endo-Surgery, Inc. | Endoscopic ancillary attachment devices |
US8007432B2 (en) | 2007-01-26 | 2011-08-30 | Ethicon Endo-Surgery, Inc. | Endoscopic accessory control mechanism |
US9254077B2 (en) | 2007-04-02 | 2016-02-09 | Cook Medical Technologies Llc | Endoscopic apparatus having an outer rail |
US8734327B2 (en) | 2008-04-29 | 2014-05-27 | Cook Medical Technologies Llc | Device platform for medical procedures |
US9486125B2 (en) | 2009-07-08 | 2016-11-08 | Endoguard Limited | Accessory clip for an endoscope |
US9723973B2 (en) | 2013-08-20 | 2017-08-08 | Cook Medical Technologies Llc | Endoscope mountable visualization device and handle |
US20150164307A1 (en) | 2013-12-12 | 2015-06-18 | Gyrus Acmi, Inc. (D.B.A. Olympus Surgical Technologies America) | Endoscope Tool Position Holder |
US20160089008A1 (en) | 2014-09-29 | 2016-03-31 | Cook Medical Technologies Llc | Endoscope mountable visualization device quick-connect/release handle attachment mechanism |
US20170188796A1 (en) * | 2016-01-04 | 2017-07-06 | Endovate Llc | Overtube Device and Method of Use |
US20180361055A1 (en) | 2017-06-19 | 2018-12-20 | Boston Scientific Scimed, Inc. | Automated fluid management system |
Also Published As
Publication number | Publication date |
---|---|
US20220015611A1 (en) | 2022-01-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7362918B2 (en) | fluid monitoring system | |
US11382652B2 (en) | Device guidewire management accessory | |
US20220369919A1 (en) | Endoscopic devices, access sheaths, and associated methods | |
AU2020426080B2 (en) | Fluid management system | |
US11974720B2 (en) | Medical device accessory mounting system | |
US20220362518A1 (en) | Motorized control for medical device | |
US20220400936A1 (en) | Endoscopic and fluid management systems having an electronically adjustable orifice | |
US12108985B2 (en) | Fluid management system with integrated laser fiber cooling | |
AU2022242732B2 (en) | Endoscope handle and deployment device | |
EP4340904A1 (en) | Fluid management system |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: BOSTON SCIENTIFIC SCIMED, INC., MINNESOTA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SUBASIC, JOHN;REEL/FRAME:056799/0666 Effective date: 20210517 |
|
FEPP | Fee payment procedure |
Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS |
|
ZAAB | Notice of allowance mailed |
Free format text: ORIGINAL CODE: MN/=. |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |